The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly (NYSE:LLY)'s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

A back-of-the-envelope comparison puts MariTide with a slightly better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below market ...